Sortino ratio is not yet available for VRNA. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.
How it compares to other similar stocks
The table compares Verona Pharma plc's Sortino Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how VRNA's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 23, 2026.
| Symbol | Name | 1Y Sortino Ratio | 5Y Sortino Ratio | 10Y Sortino Ratio | All Time Sortino Ratio |
|---|---|---|---|---|---|
| CARM | Carisma Therapeutics Inc. | 77.79 | |||
| ABVX | Abivax SA American Depositary Shares | 13.18 | |||
| INKT | MiNK Therapeutics, Inc. | 8.54 | |||
| NKGN | NKGen Biotech Inc. Common Stock | 7.53 | |||
| PROK | ProKidney Corp. | 7.52 | |||
| COGT | Cogent Biosciences, Inc. | 7.27 | |||
| NKTR | Nektar Therapeutics | 6.83 | |||
| PRAX | Praxis Precision Medicines, Inc. | 6.70 | |||
| ALMS | Alumis Inc | 6.47 | |||
| SYRE | Spyre Therapeutics Inc. | 6.29 | |||
| VRNA | Verona Pharma plc | — |
Historical Sortino Ratio
The chart shows VRNA's rolling Sortino ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to downside risk, while declining trends may signal deteriorating risk-adjusted performance or increased volatility during market stress. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.
Identify market cycles by observing when VRNA consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.
Loading charts...
IHow does VRNA fit in your portfolio?
Add your other holdings to see your portfolio's Sortino Ratio and find out.
Analyze Your Portfolio